诺诚健华2025大事记(文末有彩蛋)

诺诚健华INNOCARE
Feb 14

2025年1412月奥布替尼治疗SLE IIb期研究达到主要终点 并获批III期注册临床试验1112月中国首款自主研发的新一代TRK抑制剂宜诺欣®(佐来曲替尼)获批上市0912月2025 ASH | 诺诚健华新型BCL2抑制剂Mesutoclax最新临床数据闪耀第67届美国血液学会年会2811月诺诚健华新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10